Retatrutide Weight Loss Results: What Clinical Trials Have Found

Interest in Retatrutide as a weight loss treatment has grown rapidly since Phase 2 trial results were published — and for good reason. The data stands out even compared to other recent compounds in the same class. At Cameolord Pharmacy, we want patients to understand what the research actually shows before they consider any treatment pathway.

What the Phase 2 Trial Data Shows

Published Phase 2 data on Retatrutide reported weight reductions across multiple dose groups over a 48-week period. Participants in the highest dose group saw average weight reductions of around 24% at 48 weeks, with some longer-follow-up data suggesting reductions of around 28% in select groups. These are among the highest figures reported for any compound in this class to date.

The mechanism behind this is Retatrutide’s triple-agonist activity — acting on GIP, GLP-1, and glucagon receptor pathways simultaneously. The glucagon component is believed to contribute to increased energy expenditure, which may explain why weight loss figures appear higher than with dual-agonist compounds like Tirzepatide.

How Does Retatrutide Compare to Other Weight Loss Treatments?

For context, Semaglutide (Wegovy) has reported average weight losses of around 15% in trial settings, while Tirzepatide (Mounjaro) has reported around 20–22%. Retatrutide’s Phase 2 data sits above both, though it’s important to note that head-to-head trials haven’t been published and these figures come from different studies with different participant profiles.

What This Means for Patients

Clinical trial figures represent averages from controlled, supervised settings — not a guarantee for any individual. Factors including starting weight, metabolic profile, diet, and activity levels all play a role in outcomes. This is one of the reasons Cameolord Pharmacy runs a proper clinical consultation before any treatment begins — to set realistic expectations and ensure each patient has the right support throughout.

If you’re considering Retatrutide as a weight loss option, book a consultation with our team as the first step.

Frequently Asked Questions

How much weight can you lose on Retatrutide? Published Phase 2 trial data has reported average weight reductions of up to 24% at 48 weeks in the highest dose groups, though individual results vary. A proper clinical consultation helps set realistic expectations.

Is Retatrutide better than Semaglutide or Tirzepatide for weight loss? Phase 2 trial data suggests higher average weight reductions with Retatrutide compared to both, but head-to-head trials haven’t been published. Suitability depends on individual assessment.

How do I access Retatrutide through Cameolord Pharmacy? Through our clinical consultation pathway. Visit cameolordpharmacy.uk to get started.

---

This article summarises publicly available clinical trial data for general informational purposes only and does not constitute medical advice. If you are experiencing health concerns, please consult a qualified healthcare professional.